Alar Pharmaceuticals Reports Breakthrough Phase 1 Results for Long-Acting Ketamine Injectable ALA-3000 in Treatment-Resistant Depression
核心洞察
Alar Pharmaceuticals (搜索) announced positive Phase 1 results for ALA-3000, a long-acting ketamine injection that eliminates dissociation and sedation side effects commonly seen with conventional ketamine therapies.
The randomized, double-blind study demonstrated sustained antidepressant effects with early onset at 24 hours and separation from placebo beginning Day 9, achieving response rates of 60% or higher.
ALA-3000's sustained-release profile may eliminate the mandatory 2-hour post-dose monitoring requirement, potentially reducing clinic costs and improving treatment accessibility for patients with treatment-resistant depression.
Alar Pharmaceuticals (搜索) Inc. has announced positive Phase 1 clinical results for ALA-3000, a proprietary long-acting ketamine injection designed to address key limitations of current ketamine therapies for treatment-resistant depression (TRD). The randomized, double-blind, placebo-controlled study represents the first-in-human evaluation of the subcutaneous formulation, which demonstrated favorable safety and sustained antidepressant effects without the dissociation and sedation typically associated with ketamine treatment.
Study Design and Safety Profile
The Phase 1 study evaluated subcutaneous administration of ALA-3000 at doses of 150 mg or 250 mg, administered one week apart, in combination with standard-of-care oral antidepressants. ALA-3000 met its primary endpoint, demonstrating a favorable safety and tolerability profile with no subjects discontinuing due to adverse events.
Treatment-related adverse events were mild to moderate in severity, including injection site reactions, headache, and diarrhea, all of which were transient and resolvable. Notably, the study revealed no clinically meaningful safety concerns, including no blood pressure elevations or signals related to abuse potential or urinary adverse events.
Most significantly, no dissociation, sedation, or psychosis-like symptoms were observed. Mean total scores on the Clinician-Administered Dissociative States Scale (CADSS) remained negligible (≤0.7) and comparable to placebo, with no dissociation-related adverse events reported. All subjects remained fully alert throughout the study, indicating a complete absence of sedative effects.
Sustained-Release Pharmacokinetics
Pharmacokinetic results demonstrated that ALA-3000 delivers sustained ketamine exposure over several weeks following two administrations. Plasma concentrations of ketamine increased gradually, without the pronounced peak levels typically associated with immediate-release ketamine formulations. No dose dumping was observed, and ketamine exposure remained steady throughout the study period.
Efficacy Outcomes
In exploratory efficacy endpoints, ALA-3000 demonstrated rapid and sustained antidepressant effects as assessed by the Montgomery–Åsberg Depression Rating Scale (MADRS). Key findings included early onset with MADRS total scores decreasing as early as 24 hours post-dose and separation from placebo beginning Day 9.
From Day 9 to Day 36, ALA-3000 demonstrated approximately 3 to 6 points (150 mg dose) and 2 to 4 points (250 mg dose) greater reduction versus placebo. Response rates reached ≥60% for the 150 mg dose and 54% to 69% for the 250 mg dose, compared to 36% to 45% for placebo from Day 11 to Day 36.
Remission rates from Day 22 to Day 36 reached 50% for the 150 mg dose and 23% to 31% for the 250 mg dose, versus 18% for placebo, highlighting the clinically meaningful antidepressant benefit of ALA-3000 in treatment-resistant depression.
Clinical Advantages and Market Impact
The sustained-release profile of ALA-3000 may offer significant clinical advantages by eliminating the need for mandatory prolonged post-dose clinical monitoring required by current ketamine therapies. By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, potentially reducing clinic operating costs, improving patient throughput, and supporting a more cost-effective and reimbursement-aligned treatment model.
"ALA-3000 is supported by a robust global intellectual property portfolio, including composition of matter, polymorph, and formulation patents granted across major markets," said Yung-Shun Wen, CEO of Alar Pharmaceuticals (搜索). "The clinical results validate our differentiated product and position ALA-3000 as a compelling candidate for global development and licensing partnerships."
Charles Lin, Founder and Chairman of Alar Pharmaceuticals (搜索), noted that while ketamine has shown robust clinical efficacy in TRD and holds promise in other indications such as post-traumatic stress disorder, fibromyalgia, and Parkinson's disease, "its clinical utility has been constrained by pharmacokinetic limitations and psychiatric safety concerns. ALA-3000 is designed to overcome these barriers, enabling broader adoption and maximizing its therapeutic and commercial value."
Future Development
The positive Phase 1 results support continued clinical development of ALA-3000, with the company positioning the treatment as a potential breakthrough in ketamine therapy that could expand accessibility to a broader patient population by reducing reliance on psychedelic-assisted psychotherapy and eliminating intensive monitoring requirements.